AzurRx BioPharma, Inc. (NASDAQ: AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that Daniel Schneiderman has been appointed to serve as the Company's Chief Financial Officer effective January 2, 2020.

Mr. Schneiderman, who has over 17 years of healthcare and finance experience, most recently served as Chief Financial Officer for Biophytis, SA (through its U.S. subsidiary Biophytis, Inc.) (Euronext Growth Paris: ALBPS) from November 2018 through December 2019. Previously, Mr. Schneiderman served as the Vice President, Finance, Controller and Corporate Secretary for MetaStat, Inc. from February 2012 through October 2018. Mr. Schneiderman's early career included a number of investment banking positions where he focused on private and public small capitalization companies mainly in the healthcare and life sciences sectors. Mr. Schneiderman was Vice President of Investment Banking for Burnham Hill Partners LLC, where he worked from 2008 to 2012. From 2004 through 2008, Mr. Schneiderman was Vice President of Investment Banking at Burnham Hill Partners, a division of Pali Capital, Inc. Previously, Mr. Schneiderman worked at H.C. Wainwright & Co., Inc. in 2004 as an investment banking analyst. Mr. Schneiderman earned a bachelor's degree in economics from Tulane University. Mr. Schneiderrman replaces Maged Shenouda, who left the Company on November 30, 2019 to pursue other career opportunities.

"We are very pleased that Daniel Schneiderman is joining AzurRx as Chief Financial Officer. I am confident that his vast healthcare, financial, strategic and fundraising experience will allow him to make a significant contribution to the Company's future success," commented James Sapirstein, President and Chief Executive Officer.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.